Epoch 52: 10 Biotech Buyout Predictions for 2025

MDGL VKTX ITCI AXSM LEGN ARWR XENE IDYA PLRX

Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. This will be our last strategy article of 2024 - thank you for your support if you have been reading throughout the year! Today we will be diving into the topic of biotech buyout candidates for 2025. We will explore which companies are most likely to be acquired by larger players. Our focus will be on companies with the potential for mega blockbuster status—those with projected peak revenues of $2B or more. We’ll discuss why these companies are attractive targets, the key factors driving their potential, and how large pharma is looking to bolster their portfolios with high-impact assets in areas like oncology, neurology, and metabolic diseases. Many of the names will be familiar as they were expected to be bought out in 2024.

If you're not subbed yet click the link below. Every Thursday we are out with our FREE public/private biotech market update. Sundays are the days we focus on forward looking strategy. Monday’s are for public equity research. Tomorrow we will once again be skipping out equity analysis and will release an article on X covering a biotech hot topic. The following week we will be back the normal schedule.

Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!

Enough shilling for the day, lots to cover this week, let's get started!

INTRODUCTION

Today we aim to predict the top 10 potential biotech buyout candidates for 2025, focusing on companies with the most promising drug candidates and high projected peak revenues. While large market caps can often signal a company is already well-established, they also present a challenge for potential acquisitions, as pharma companies typically target companies with market caps that are more affordable yet still carry significant upside potential. The goal is to identify those biotech firms that are poised to deliver “mega blockbuster” products — companies with therapies that could generate $2B to $3B or more in annual revenue. These buyouts are driven by large pharma’s need to expand their pipelines with high-impact, late-stage assets, often in areas of unmet medical need, which can offer substantial returns in the long run. As we evaluate these candidates, we will balance their market cap, growth potential, and ability to deliver on high-revenue opportunities, making them attractive targets for larger players in the industry.

With that here is the list of the top 10 potential biotech buyouts for 2025, sorted by projected peak revenue, along with the rationale for why these companies could be attractive acquisition targets.